Published on: May 07, 2018 at The Lancet

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

By : The Lancet

A new study in The Lancet explores why postoperative chemoradiotherapy does not provide a survival benefit over chemotherapy  Researchers explain preoperative treatment strategies may provide more benefit to patients who have resectable gastric cancer. 

Read More
SHARE